Precigen (PGEN) Fireside chat summary

Introduction and agenda

• Discussion focused on the commercial launch and clinical impact of Papzimeos, the first immunotherapy for adult RRP, following its FDA approval in 2025.

• Speakers included the CEO and CCO, covering clinical, commercial, and strategic aspects.

Background and experience of the speaker

• CEO has extensive experience in developing therapies, emphasizing innovation in viral vector platforms.

• CCO detailed the commercial strategy and operational execution for the launch.

Current industry trends

• Shift toward immunotherapies and personalized medicine for rare diseases.

• Growing importance of platform technologies for rapid development and regulatory efficiency.